Sunday, July 26 – Recent research has found that GLP-1s, like Ozempic and Wegovy, can help you maintain a lower calorie intake for more than a year. Image Credit: Jon Challicom/Getty

A new study found that people taking semaglutide (Ozempic and Wegovy) maintained a significantly lower calorie intake after 60 weeks on the medication.

Participants taking semaglutide consistently consumed 24% to 30% fewer calories than those receiving a placebo throughout the study.

The findings suggest semaglutide may continue supporting weight loss even after differences in hunger and food cravings begin to fade.

Sunday, July 26 – Prescribing doctors often warn of the medications’ potential side-effects – but unexpected impacts on romantic relationships are less understoodFor Jennifer, obesity was the obvious culprit for most of her problems.The litigation attorney told herself it was the reason why she wasn’t being invited to parties, and why she and her husband struggled with physical intimacy in their otherwise “solid” marriage.Sign up for a weekly email featuring our best reads Continue reading…

Sunday, July 26 – (MedPage Today) — TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical…

Sunday, July 26 – (MedPage Today) — Starting a GLP-1 receptor agonist for type 2 diabetes was associated with a lower risk of fragility fractures in adults 50 and older, including hip and vertebral fractures, according to a large target trial emulation study….

Sunday, July 26 – Newer oral drugs related to semaglutide medications such as Ozempic reduced pleasure-driven eating in mice by quieting a deep brain reward circuit. The finding could open new avenues for understanding food cravings and potentially treating substance use disorder.

Sunday, July 26 – Research into GLP-1 medications is not always robust but complaints such as digestive problems are well knownWeight loss jabs such as Wegovy and Mounjaro have boomed in popularity, and so have reports of myriad side-effects. This week researchers have suggested GLP-1 medications could be associated with hair loss.It can be hard to keep tabs on which of these unintentional outcomes have been the subject of expert scrutiny and which remain little more than hearsay. We take a look at some of the most talked about side-effects and explore which have been studied – and which remain unproven. Continue reading…

Saturday, July 25 – “This medicine erased years and years of self-hate, cured my eating disorder, reduced the pain in my body and improved my intracranial hypertension.”View Entire Post ›

Saturday, July 25 – (MedPage Today) — You passed medical training, now see if you can pass our weekly quiz

Saturday, July 25 – Novo Nordisk Inc. asked a New Jersey federal court Friday to block rival Eli Lilly & Co. from running ads allegedly comparing their respective GLP-1 drugs using “outdated” clinical trials and “false superiority messages,” arguing the ads are damaging its reputation and misleading consumers.

Saturday, July 25 – Stanford Medicine researchers have discovered a naturally occurring molecule that may suppress appetite and reduce body weight much like Ozempic, but without several of its common side effects. The molecule, called BRP, acts on a more targeted region of the brain involved in hunger and metabolism rather than affecting tissues throughout the body.

Saturday, July 25 – Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety risks.

Saturday, July 25 – A large study suggests that GLP-1 drugs including Ozempic and Mounjaro may slightly increase the risk of hair loss in people with type 2 diabetes. Compared with two other common classes of diabetes medications, GLP-1 users had a significantly higher rate of alopecia, though the absolute risk was still low. The hair loss was mainly non-scarring, which means it may be reversible.

Friday, July 24 – Scoring high marks on two more phase III obesity trials, this time involving serious type 2 diabetes and cardiovascular complications, Eli Lilly and Co. has cleared the path for a BLA filing for its triple-G candidate retatrutide, which many expect will eventually surpass the top two marketed drugs in the space.

Friday, July 24 – Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare disease? Find out on this week’s episode of…

Thursday, July 23 – July The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, a study published by The BMJ finds. Although the absolute risk is low, awareness of this potential effect may help inform shared treatment decisions, the researchers say.

Thursday, July 23 – (MedPage Today) — Adults with type 2 diabetes who used a GLP-1 receptor agonist had an increased risk of clinically recorded hair loss, data from a target trial emulation suggested.
Compared with other antidiabetic medications, GLP-1 drug use…

Thursday, July 23 – (MedPage Today) — The use of GLP-1 receptor agonists was associated with a lower risk of alcohol-related hospitalization in adults with alcohol addiction, a retrospective study found. (BMJ Open)
GLP-1 drugs for obesity were linked with reduced…

Wednesday, July 22 – People taking semaglutide for weight loss continued to consume significantly fewer calories after 60 weeks on the medication, helping explain how the medication supports both initial weight loss and long-term weight maintenance. The study, published in the American Journal of Clinical Nutrition and led by investigators from Penn’s Center for Weight and Eating Disorders and Penn Metabolic Medicine, is among the first to examine the long-term effects of semaglutide on eating behavior beyond the initial months of treatment.

Wednesday, July 22 – GLP-1 receptor agonists are among the active ingredients in so-called weight-loss injections. Originally developed to treat type 2 diabetes, they are now also used to treat severe obesity. In recent years, studies have provided evidence that they may also reduce the consumption of alcohol and other substances. However, it has not been clear whether these potential effects persist after the medication is discontinued.

Wednesday, July 22 – The attorneys general of Texas and Louisiana pushed back on Tuesday against a bid from Novo Nordisk and Eli Lilly to duck a specialty pharmacy’s antitrust case accusing the companies of blocking competition for GLP-1 medications.

Wednesday, July 22 – Pharmaceutical giant Novo Nordisk Inc. slapped rival Eli Lilly & Co. with a false advertising suit in New Jersey federal court Tuesday, calling a marketing campaign for the rival’s weight loss drugs “deceptive” for “withholding critical scientific evidence” about newer GLP-1 formulations.

Wednesday, July 22 – (MedPage Today) — Novo Nordisk sued rival drugmaker Eli Lilly, alleging false advertising claims about relative weight-loss drug performance. (Reuters via NBC News)
GLP-1 drug use surged from 2017 to 2022, jumping 230% in adults with diabetes…

Wednesday, July 22 – Here’s how weight-loss drugs like Ozempic and Wegovy could reduce worker illness and save companies money.

Wednesday, July 22 – Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effectiveOzempic maker Novo Nordisk said on Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.The Danish pharmaceuticals heavyweight complained that the US group – which makes rival weight-loss treatments Zepbound and Mounjaro – “intentionally selected outdated studies” that compared Lilly’s highest doses against lower doses of Novo Nordisk’s medicines. Continue reading…

Wednesday, July 22 – Novo Nordisk has launched legal action accusing Eli Lilly of creating “misleading” ads, a claim its rival denies.

Wednesday, July 22 – Novo Nordisk, which makes Ozempic and Wegovy, has filed a federal lawsuit against Eli Lilly, accusing its competitor of false advertising and unfair competition. Novo Nordisk challenges national ad campaigns from Eli Lilly that compare GLP-1 drugs from both companies, saying that Lilly intentionally relies on outdated clinical trials to paint a false and misleading picture. NBC’s Christine Romans joins TODAY with the details.

Wednesday, July 22 – Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.

Tuesday, July 21 – Adolescents and young adults in the U.S. are increasingly using popular GLP-1 weight-loss drugs alone or in conjunction with metabolic and bariatric surgery (MBS) to manage obesity, according to a study by UT Southwestern Medical Center researchers published in JAMA Pediatrics.

Tuesday, July 21 – (MedPage Today) — The market for compounded GLP-1 drugs remained robust despite the end of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) shortages, with many facilities adding ingredients like B vitamins and some operating…

Tuesday, July 21 – Despite growing evidence that GLP-1 medications improve health and are worth their cost, many insurance plans still limit coverage. University of Mississippi researchers are examining why and where that leaves patients.

Tuesday, July 21 – New research being presented at the International Congress on Obesity (ICO2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (15–17 July), shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss in children of various ages without diabetes are safe and effective. The study is by Dr. Manpreet Kaur Oberoi of the University of Western Ontario in London, Ontario, Canada, and colleagues.

Tuesday, July 21 – From headlines and social media, psychedelic therapies, cannabis use and GLP-1 medications have seemingly become commonplace overnight, but the science underlying these treatments and the pathway to drug approval are often more nuanced than the headlines suggest.

Monday, July 20 – “I’m the one that has to live in my body, I’m doing what I need to get my life back, and that’s all that matters.”View Entire Post ›

Sunday, July 19 – (MedPage Today) — I spent 10 minutes in complete silence in my patient’s room today, my eyes scanning lines of text in the electronic medical record. I wasn’t looking for a life-threatening lab value or an undiscovered malignancy. I was hunting…

Saturday, July 18 – GLP-1 medications like Ozempic and Wegovy may help ease symptoms of binge eating disorder and related eating behaviors. Giselleflissak/Getty Images

A new study found that GLP-1RAs could reduce key symptoms of binge eating disorder.

These included binge eating severity, loss of control eating, and emotional eating.

Experts say that GLP-1RAs could potentially augment existing treatments for binge eating disorder, like psychotherapy.

Saturday, July 18 – A new report states that older adults using GLP-1 drugs may have a higher risk of loss of muscle mass, malnutrition, dehydration, and other frailty-associated conditions. Getty Images

A new report states that older adults using GLP-1 drugs may have a higher risk of loss of muscle mass, malnutrition, and dehydration.

However, the benefits of taking these drugs should be weighed against these risks when the medications are prescribed.

Saturday, July 18 – An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—a type of medication that mimics the GLP-1 hormone—to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.

Saturday, July 18 – Researchers at the University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis.

Saturday, July 18 – Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

Friday, July 17 – Some people using GLP-1 drugs for weight loss have reported changes in their feet. Image Credit: stockvisual/Getty

“Ozempic feet” is the latest anecdotal side effect of GLP-1 drugs for weight loss.

The unusual phenomenon is a result of rapid weight loss, which may cause foot pain, changes in shoe size, and a more bony appearance in the feet.